Background
PAH is a serious yet poorly understood disease characterized by elevated pulmonary artery pressure and vascular resistance and may ultimately result in right heart failure and death. The burden of small pulmonary arteries increases due to the contraction of vascular smooth muscle cells, which plays a crucial role in regulating of pulmonary vascular resistance and in the development of PAH [
1]. However, the regulatory mechanism of the contraction of intrapulmonary arteries is poorly understood, and further investigations, especially those on molecular biomarkers, are essential for decoding the underlying pathogenic mechanism of PAH.
The NO-sGC-cGMP pathway is closely associated with PAH. cGMP exerts its biological activity mainly via three main groups of down-stream targets: cGMP-dependent protein kinases, cGMP-gated cation channels, and phosphodiesterases. Malfunctions in NO production, sGC activity, and cGMP degradation cause pulmonary arterial vasodilatation through abnormal vascular smooth muscle cell proliferation and platelet aggregation [
2].
Our previous study found that the activation of NO-sGC-cGMP pathway led to abnormal expression of multiple genes including SERPINB2, MMP1, GREM1, and IL8 [
3]. We have demonstrated that SERPINB2, also known as PAI-2, suppresses the proliferation and migration of cultured HPASMCs and speeds their apoptosis [
4]. The mRNA level of PAl-2 in peripheral blood cells of PAH patients was significantly decreased and the expression of PAl-2 was up-regulated by sGC activator. PAI-2 can be used as a potential biomarker for vascular remodeling of PAH [
5]. MMP1 encodes matrix metalloprotease-1, a member of the matrix metalloprotease (MMP) family, which are the major proteases involved in tissue remodelling of the extracellular matrix by degrading all types of matrix components. Therefore, NO-sGC-cGMP pathway may assuage or reverse the vascular remodeling in PAH by regulating genes including PAl-2 and MMP1.
However, besides these downstream-regulated genes, little is known about the interaction proteins of cGMP. As a second messenger in cells, cGMP hardly acts as isolated species while performing its functions in vivo. In our current study, we performed the Biotin-cGMP pull-down assay to search for the proteins interacted and regulated by cGMP with a human pulmonary artery smooth muscle cell line. Fortunately, we found that cGMP interacted with tropomyosin, a key factor that regulates smooth muscle contraction. Tropomyosin regulated the productive interaction between myosins and actin by shifting its position on the actin filament. The isothermal titration calorimetry (ITC) assay was then utilized to explore the fast actin-tropomyosin-myosin complex alteration after the activation of NO-sGC-cGMP pathway. We demonstrated that actin-tropomyosin-myosin interaction was downregulated in the existence of cGMP-tropomyosin interaction competition and caused the down-regulation of muscle contraction. All these findings demonstrate the functional interaction between cGMP and tropomyosin, which is involved in the regulation of muscle contraction.
Methods
Cell culture and treatment
HPASMCs (ScienCell Research Laboratories, Carlsbad, USA), identified by immuefluorescent antibodies to α-smooth muscle actin and desmin, were isolated from human pulmonary arteries [
6]. Smooth muscle cell medium (ScienCell Research Laboratories, Carlsbad, USA) supplemented with 2% fetal bovine serum and 1% smooth muscle cell growth supplement was utilized. HPASMCs were then maintained at 37 °C humidified atmosphere of 5% carbondioxide. P3 ~ P5 cells were used for experiments. The exponentially growing HPASMCs were treated with 100 μM of 8-Br-cGMP (Sigma–Aldrich Corp., St. Louis, USA) for 24 h.
Biotin-cGMP pull-down assay
10 μM of Biotin-cGMP and the negative control Biotin (Biolog life science institute, Bremen, Germany) were nurtured in a mix of whole HPASMC cell lysates at 4 °C for 6 h with gentle rotation. Biotin-cGMP fusion protein and Biotin protein were then attached to 100 μl of streptavidin magnetic beads at 4 °C for 6 h. After being gently washed by lysis buffer for 3–5 times gently to reduce nonspecific binding, beads were incubated with 50 μl of glycine elution buffer (100 mM, PH 2.5) for 10 min. Then, 10 μl of NH4HCO3 neutralization buffer was added to each elution collection tube to neutralize the pH of the contents upon elution. The elution fractions were boiled in sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS–PAGE) loading buffer and analyzed by silver staining method or immune blotting analysis. After having been excised, protein bands were subjected to in-gel trypsin digestion and analysed by mass spectrometry.
Total RNAs were extracted from HPASMCs with Trizol reagent (Invitrogen Life Technologies, Carlsberg, USA), following the manufacturer’s protocol (Invitrogen). The reverse transcription was performed with the total RNAs (2 μg) and the Moloney Murine Leukemia Virus reverse transcription kit (Invitrogen Life Technologies, Carlsberg, USA).
Real-time PCR was performed to quantify TPM1 gene, and expression of the internal control gene ACTIN was determined by iQ5 Multicolor Real-time PCR Detection System (Bio-Rad Laboratories, Hercules, CA, USA). The PCR reaction used 9.9 μl of distilled water, 12.5 μl of 2X SYBR® Premix Ex TaqTMII, 0.8 μl each for primers, and 1 μl of DNA template, constructing a total volume of 25 μl. The two-step PCR protocol was performed using SYBR® Premix Ex TaqTM II (Takara Biotech Co., Dalian, China) following the manufacturer’s instruction. It included one cycle of 95 °C for 30 s, 40 cycles of 95 °C for 5 s, and 60 °C for 30 s. Each reaction was run in triplicate. The Ct values for relative quantification of gene expression were used to determine the TPM1 expression levels. The PCR primers for TPM1 were as follows: 5’-GCTGCAGAGGATAAGTACTC-3′ (forward), 5’-CATGTTGTTTAACTCCAGT-3′ (reverse); β-ACTIN 5’-GGCGGCACCACCATGTACCCT-3′ (forward), 5’-AGGGGCCGGACTCGTCATACT -3′ (reverse). The PCR primers for TPM1 gene isoforms were as follows: Primer 1: 5′- CGGTCGCCCCCTTGGGAAAG -3′ (forward), 5′- GCTTGTCGGAAAGGACCTTGATCTC -3′ (reverse); Primer 2: 5′- AGTGAGAGAGGCATGAAAGTC -3′ (forward), 5′- AATTTAGTTACTGACCTCTCCGCA -3′ (reverse); Primer 3: 5′- CGGGCTGAGTTTGCGGAGAGG -3′ (forward), 5′- AAGGAATGGAAGTCTCGGAAGA -3′ (reverse).
Protein isolation and Western blot
Cells were collected and rinsed with PBS solution, and the protein was extracted by using the protein lysis buffer (including 1% NP-40, 1 μg/ml aprotinin, 1 μg/ml leupeptin, and 100 μg/ml PMSF). The protein concentration was assessed with a Bio-Rad DC Protein Assay (Bio-Rad, Hercules, USA). Then, 50 μg of proteins were used for sodium dodecyl sulphate-polyacrylamide gel electrophoresis. Subsequently, the proteins were transferred to nitrocellulose membranes by electro blotting (Millipore Corp., Boston, USA). Membranes were blocked in 5% milk, washed with PBST (PBS with 0.1% Tween), and incubated with 1:1000 anti-tropomyosin antibody (cell signaling technology, Danvers, USA) at 4 °C for 12 h and 0.4 μg/ml anti-actin antibody (ZSBIO, Beijing, China) at 4 °C for 1 h. After the washing and incubation with 0.08 μg/ml horseradish peroxidase-conjugated anti-IgG antibody (ZSBIO, Beijing, China) at 4 °C for 1 h in 5% milk, the membranes were washed for three times and subjected to the enhanced chemiluminescent reagents (Millipore Corp., Boston, USA) for the distinction of protein bands.
Immunofluorescence assay
Cells were grown and treated with 8-Br-cGMP on cover slips. Cultured cells were affixed with methanol at room temperature for 20 min. After being washed with PBS for three times, cover slips were blocked for 60 min in BSA blocking buffer, then incubated with diluted primary antibody at room temperature for 2 h. Cells were rinsed in PBS three times (for 5 min each), then incubated with diluted fluorochrome-conjugated secondary antibody (ZSBIO, Beijing, China) at room temperature for 1 h in dark. After stained with DAPI and stored with mounting medium, the samples were examined under confocal microscope.
Isothermal titration calorimetry assay
Interaction analysis among actin, myosin, and tropomyosin were performed at 298 K (degree kelvin) with a MicroCal Isothermal Titration Calorimeter ITC200 instrument (Malvern, England). The investigations were performed according to a strictly standardized protocol [
7‐
9]. The highly purified proteins were prepared by Sephadex G-50 column with automated protein separation chromatography system (Jinhua Inc., Shanghai, China). Typically, the syringe was filled with 60 μL of protein solution at a concentration of 0.05 μM that subsequently titrated into a 300 μL protein with the concentration of 0.005 μM in the cell. There were twenty injections of 2 μL each with a spacing of 120 s between injections employed to allow the system to reach the equilibrium. Heat generated by titrant dilution was tested by a control experiment, titrating into buffer alone, in uniform arragements. On the basis of a self-sufficient binding sites model, the MicroCal-Origin 7.0 software was applied to fit the integrated heat data of the titrations by a non-linear least-squares minimization algorithm.
The fitting parameters were ΔH (reaction enthalpy change in cal mol− 1), ΔS (the changes in entropyin cal mol− 1), K (the inverse of equilibrium binding constant in M− 1), and N (molar ratio of the proteins in the complex). Δ H value is equal to the constant pressure heat of reaction. The positive value of Δ H means heat absorption and the negative value represents heat release. Entropy is a measure of system disorder. ΔS associates with the change in the amount of substance before and after reaction in the system.Gibbs free energy (ΔG) had a relationship with ΔH that was ΔG = ΔH-TΔS = -RTlnKa (R = 8.314 J mol− 1 K− 1, T = 298.15 K), which was applied to calculate the reaction energy eventually. All the ΔG obtained by calculation testified the spontaneous reactions in our experiments.
Statistical analysis
All data attained in triplicate independent experiments were assessed via SPSS statistics 20.0 and GraphPad prism 5 (GraphPad software, Inc., La Jolla, USA). Data are showed as mean ± SD. Statistical comparisons were carried out with the student t test for investigating two-group data. A P value of < 0.05 was considered statistically significant
Discussion
Smooth muscle cell is the most important regulator of the blood vessel contraction in the body. Smooth muscle contraction can be caused by several physiochemical agents. The ectopic regulation of NO production, sGC activity and cGMP degradation contributes to the development of pulmonary vasorelaxation, which is closely related to the effect of smooth muscle cell. Riociguat (BAY 63–2521), the sGC stimulator, has a dual effect on PAH by promoting pulmonary vasorelaxation and reducing fibrosis [
13]. However, the molecular mechanism by which NO-sGC-cGMP pathway causes pulmonary vasorelaxation remains undefined.
In this study, by performing Biotin-cGMP pull-down assay and ITC analysis, we found that cGMP interacted with tropomyosin, which lead to the structural and functional alterations in the actin-tropomyosin-myosin complex. Tropomyosin, as a coiled-coil molecule which associates head-to-tail to form super-helical polymers, has 284 aa in length with a molecular mass of about 33 kDa [
14]. Mammals utilize
TPM1,
TPM2,
TPM3, and
TPM4 to express more than 40 tropomyosin isoforms by alternative splicing [
15]. The functions of isoforms are variables determined by the timing and tissue specificity of gene expression, mRNA, and protein localization. For example, tropomyosin 4 [
16] expression is enhanced and tropomyosin 1 [
17] expression is altered in smooth muscle cells shifting from a contractile to a synthetic phenotype. Tropomyosin 6 is a relatively late marker for smooth muscle maturation in both mice and human beings [
18]. Thus, the diverse functions of tropomyosin isoforms have offered an impressive mechanism to illustrate the variation of actin-myosin interaction in different intracellular compartments [
19]. We performed PCR using primers designed based on the non-conserved sequences and found that isoform 4 was the only isoform expressed in our HPASMCs.
It is becoming increasingly clear that muscle contraction is controlled by the sliding filament mechanism, whose central feature is the interplay of myosin with actin filaments [
20]. The heads of myosin in the thick filament bind to actin in the thin filament (made of actin and tropomyosin) as induced by some physiochemical signals. Tropomyosin plays a crucial role in the regulating the interaction between actin and myosin and altering the sliding of myosin filaments, thus serving as a regulator of muscle contraction [
21].
In our current study, we demonstrated that there was an interaction between cGMP and tropomyosin, and the cGMP binding site was aa 68–208 of the tropomyosin protein. According to the 3-D protein structure from the Protein Data Bank (PDB,
https://www.rcsb.org/), aa 98–233 of tropomyosin is the key fragment that regulates the interaction between myosin and actin. Thus, cGMP and tropomyosin interaction may compete to the binding site of tropomyosin and actin, finally leading to the decrease of the interaction between myosin and actin. This was in accordance with the “steric blocking mechanism” that the migration of tropomyosin into the center of the filament groove increases the interaction between the myosin head and actin [
20].
Furthermore, smooth muscle contraction is set up in motion by the discharge of Ca
2+ [
22‐
24]. ATPase is also needed during the contraction [
25]. Therefore, Ca
2+ and ATPase can be added to the mixure for ITC assay, permitting the myosin head to interact with the actin filament and cause contraction.
We also found in our study that, although cGMP interacted with tropomyosin, it had no effect on tropomyosin expression and subcellular localization. The expression of tropomyosin can be regulated by other factors; for example, miR-21 can down-regulate
TPM1 to inhibit tumor growth, and thus miR-21 functions as an oncogene [
26]. Another second messenger cAMP also negatively regulates the mRNA level of tropomyosin in cultured rat vascular smooth muscle cells [
27]. We assume that there are two main ways of tropomyosin to exert its functions: one way is the activated pathway, in which expression and localization are adjusted by unique signals or modifications; and the other way is the physical interaction, i.e. tropomyosin exerts crucial functions via its interactions with other critical cellular proteins.
This preliminary study clearly demonstrated an interaction of cGMP with tropomyosin, although we still have no data on cGMP-tropomyosin interaction in vivo. In addition to investigations on the pulmonary artery pressure after the increase of cGMP level in tropomyosin 1 knock-out mice, and hPASMC contraction after cGMP increase and TPM1 knockdown, we also will detect the cGMP-tropomyosin interaction in PAH mice. Also, the structure of cGMP and actin-tropomyosin-myosin complex need be further defined with methods such as x-ray diffraction and electron microscopy.